backHealthcare industry stakeholders are predicting M&A activity will accelerate in 2024 for both private equity sponsors and strategic buyers. At the same time, legislators and regulators at both the state and federal levels have been proposing and implementing new rules and regulations and adopting new enforcement priorities in response to growing private equity investment in the industry and consolidation among both for-profit and nonprofit health systems. Dealmakers must navigate a changing regulatory landscape that includes aggressive antitrust scrutiny, new requirements for state-level review of healthcare deals, expansive ownership disclosure requirements and more.
King & Spalding will host a one-hour roundtable webinar on Wednesday, February 28, to discuss the latest developments impacting healthcare M&A. Topics for discussion will include:
- Deal market updates
- FTC enforcement trends and rulemaking updates
- Corporate Transparency Act (CTA) and other new ownership disclosure requirements
- Legislative and rulemaking developments at the state and federal levels, including transaction review/approval requirements and corporate practice of medicine restrictions
- Emerging issues for due diligence, including OIG enforcement priorities, AI, tracking technologies and more